Jason T. Olin

7.6k total citations · 1 hit paper
79 papers, 5.1k citations indexed

About

Jason T. Olin is a scholar working on Psychiatry and Mental health, Pharmacology and Physiology. According to data from OpenAlex, Jason T. Olin has authored 79 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Psychiatry and Mental health, 30 papers in Pharmacology and 17 papers in Physiology. Recurrent topics in Jason T. Olin's work include Dementia and Cognitive Impairment Research (38 papers), Cholinesterase and Neurodegenerative Diseases (21 papers) and Alzheimer's disease research and treatments (16 papers). Jason T. Olin is often cited by papers focused on Dementia and Cognitive Impairment Research (38 papers), Cholinesterase and Neurodegenerative Diseases (21 papers) and Alzheimer's disease research and treatments (16 papers). Jason T. Olin collaborates with scholars based in United States, Switzerland and India. Jason T. Olin's co-authors include Lon S. Schneider, Constantine G. Lyketsos, Frederick A. Schmitt, Michael E. Wechsler, Lara Schneider, George T. Grossberg, Rachelle S. Doody, George S. Alexopoulos, Barry D. Lebowitz and Ira R. Katz and has published in prestigious journals such as American Journal of Psychiatry, Biological Psychiatry and Cochrane Database of Systematic Reviews.

In The Last Decade

Jason T. Olin

78 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Validity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of Change

1997 528 citations Lara Schneider, Jason T. Olin et al. Alzheimer Disease & Associated Disorders profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jason T. Olin United States	34	2.5k	1.3k	1.3k	537	505	79	5.1k
Rupert McShane United Kingdom	37	2.3k 0.9×	1.0k 0.8×	1.4k 1.1×	595 1.1×	570 1.1×	96	5.3k
Jacobo Mintzer United States	40	3.7k 1.5×	1.3k 1.0×	1.3k 1.0×	700 1.3×	592 1.2×	137	6.0k
Anton P. Porsteinsson United States	37	3.0k 1.2×	2.4k 1.8×	1.3k 1.0×	701 1.3×	722 1.4×	129	5.9k
Anne Corbett United Kingdom	45	2.6k 1.0×	1.8k 1.4×	987 0.8×	1.0k 1.9×	618 1.2×	168	8.0k
Alasdair M. Barr Canada	48	2.0k 0.8×	1.1k 0.8×	765 0.6×	904 1.7×	342 0.7×	222	7.5k
Kazuo Hasegawa Japan	12	2.5k 1.0×	1.5k 1.1×	440 0.3×	462 0.9×	579 1.1×	26	5.2k
Ashwin A. Patkar United States	44	2.0k 0.8×	933 0.7×	1.8k 1.4×	598 1.1×	195 0.4×	282	7.2k
Eva von Strauss Sweden	36	2.3k 0.9×	1.3k 1.0×	341 0.3×	642 1.2×	484 1.0×	77	5.4k
J. Wesson Ashford United States	39	2.0k 0.8×	2.0k 1.5×	485 0.4×	868 1.6×	515 1.0×	147	5.2k
Peter Bentham United Kingdom	28	1.2k 0.5×	989 0.8×	707 0.6×	241 0.4×	380 0.8×	63	3.2k

Countries citing papers authored by Jason T. Olin

Since Specialization

Citations

This map shows the geographic impact of Jason T. Olin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jason T. Olin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jason T. Olin more than expected).

Fields of papers citing papers by Jason T. Olin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jason T. Olin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jason T. Olin. The network helps show where Jason T. Olin may publish in the future.

Co-authorship network of co-authors of Jason T. Olin

This figure shows the co-authorship network connecting the top 25 collaborators of Jason T. Olin. A scholar is included among the top collaborators of Jason T. Olin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jason T. Olin. Jason T. Olin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Olin, Jason T., et al.. (2024). Swimming Induced Pulmonary Edema: A Case Report and Review of the Literature. A6003–A6003.

Joseph, Warren S., Tracey C. Vlahovic, Radhakrishnan Pillai, & Jason T. Olin. (2014). Efinaconazole 10% Solution in the Treatment of Onychomycosis of the Toenails. Journal of the American Podiatric Medical Association. 104(5). 479–485. 1 indexed citations

Elewski, Boni E., Phoebe Rich, Richard Pollak, et al.. (2012). Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. Journal of the American Academy of Dermatology. 68(4). 600–608. 167 indexed citations

Grossberg, George T., Jason T. Olin, Monique Somogyi, & Xingqiong Meng. (2011). Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer’s disease. International Journal of Clinical Practice. 65(4). 465–471. 17 indexed citations

Cummings, Jeffrey L., Steven H. Ferris, Martin R. Farlow, Jason T. Olin, & Xiangyi Meng. (2010). Effects of Rivastigmine Transdermal Patch and Capsule on Aspects of Clinical Global Impression of Change in Alzheimer’s Disease: A Retrospective Analysis. Dementia and Geriatric Cognitive Disorders. 29(5). 406–412. 10 indexed citations

Farlow, Martin R., George T. Grossberg, Serge Gauthier, Xiangyi Meng, & Jason T. Olin. (2010). The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease. Current Medical Research and Opinion. 26(10). 2441–2447. 25 indexed citations

Farlow, Martin R., George T. Grossberg, Xiangyi Meng, Jason T. Olin, & Monique Somogyi. (2010). Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. International Journal of Geriatric Psychiatry. 26(12). 1236–1243. 25 indexed citations

Olin, Jason T., et al.. (2009). Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26‐week, open‐label, prospective trial (Study ENA713B US32). International Journal of Geriatric Psychiatry. 25(4). 419–426. 32 indexed citations

Cummings, Jeffrey L., Martin R. Farlow, Xiangyi Meng, Sibel Tekin, & Jason T. Olin. (2009). Rivastigmine Transdermal Patch Skin Tolerability. Clinical Drug Investigation. 30(1). 41–49. 27 indexed citations

10.

Williams, Janet B. W., Kenneth A. Kobak, Per Bech, et al.. (2008). The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. International Clinical Psychopharmacology. 23(3). 120–129. 231 indexed citations

11.

Dyck, Christopher H. van, Frederick A. Schmitt, & Jason T. Olin. (2006). A Responder Analysis of Memantine Treatment in Patients With Alzheimer Disease Maintained on Donepezil. American Journal of Geriatric Psychiatry. 14(5). 428–437. 50 indexed citations

12.

Schmitt, Frederick A., Christopher H. van Dyck, Christine H. Wichems, & Jason T. Olin. (2006). Cognitive Response to Memantine in Moderate to Severe Alzheimer Disease Patients Already Receiving Donepezil. Alzheimer Disease & Associated Disorders. 20(4). 255–262. 51 indexed citations

13.

Olin, Jason T., Lon S. Schneider, Ira R. Katz, et al.. (2003). Provisional diagnostic criteria for depression of Alzheimer’s disease: description and review. Expert Review of Neurotherapeutics. 3(1). 99–106. 34 indexed citations

14.

Olin, Jason T. & Lara Schneider. (2002). Galantamine for dementia due to Alzheimer's disease. Cochrane Database of Systematic Reviews. CD001747–CD001747. 83 indexed citations

15.

Krishnan, K. Ranga, Mahlon R. DeLong, Helena C. Kraemer, et al.. (2002). Comorbidity of depression with other medical diseases in the elderly. Biological Psychiatry. 52(6). 559–588. 206 indexed citations

16.

Alexopoulos, George S., Soo Borson, Bruce N. Cuthbert, et al.. (2002). Assessment of late life depression. Biological Psychiatry. 52(3). 164–174. 111 indexed citations

17.

Schneider, Lara, Jason T. Olin, Rachelle S. Doody, et al.. (1997). Validity and Reliability of the Alzheimerʼs Disease Cooperative Study-Clinical Global Impression of Change. Alzheimer Disease & Associated Disorders. 11. 22–32. 528 indexed citations breakdown →

18.

Schneider, Lon S., Jason T. Olin, Scott A. Lyness, & Helena C. Chui. (1997). Eligibility of Alzheimer's Disease Clinic Patients for Clinical Trials. Journal of the American Geriatrics Society. 45(8). 923–928. 101 indexed citations

19.

Schneider, Lon S. & Jason T. Olin. (1996). Clinical Global Impression of Change Clinical Global Impressions in Alzheimer’s Clinical Trials. International Psychogeriatrics. 8(2). 277–290. 79 indexed citations

20.

Schneider, Lon S. & Jason T. Olin. (1994). Overview of Clinical Trials of Hydergine in Dementia. Archives of Neurology. 51(8). 787–798. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact